SOLIGENIX, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On April 13, Soligenix, Inc. (the "Company") issued a press release announcing planned conference presentations scheduled during April and May 2021. The presentations will focus on the HyBryte™ (SGX301 or synthetic hypericin) cutaneous T-cell lymphoma (CTCL) program, including elaboration on previously released efficacy and safety outcomes in the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) study, and will provide an update on the CiVax™ (COVID-19 subunit vaccine) program, including review of data from pre-clinical studies.

The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)  Exhibits.



Exhibit No.   Description
99.1            Press release of Soligenix, Inc. dated April 13, 2021.




                                       1

© Edgar Online, source Glimpses